Promising Results from Study but More Work Needed for Healthcare Equity in Kenya

By Staff Writer

August 31, 2023

The African Health Markets for Equity (AHME) program has shown encouraging results in improving access to and quality of private health clinics in Kenya, according to a recent study. The research, a cluster randomised controlled trial, aimed to determine if the combination of social health insurance and management training could enhance healthcare services in the country.

The study revealed that AHME significantly impacted clinics, with the treatment group reporting a 26.0% increase in total clients and a 51.3% increase in National Hospital Insurance Fund (NHIF) clients. AHME also increased the likelihood of individuals having any form of health insurance, whether public or private.

However, the study did not find that AHME was successful in promoting pro-poor private healthcare. Poor households were significantly less likely to have health insurance, and there was no additional effect of AHME for this group. The study also found that AHME did not improve the quality of care for poor clients.

AHME focused on social health insurance as a mechanism for low-income households to receive high-quality healthcare at private or public clinics. The intervention encouraged and assisted private clinics to register under the NHIF scheme. This resulted in large effects on clinic registration and significant increases in the number of clients with public insurance served.

Despite these positive outcomes, more work is needed to improve insurance enrollment for poorer households. The study suggests that future research should focus on understanding the mechanisms through which increased clinic NHIF registration might increase demand-side insurance enrollment.

Reference url

Recent Posts

masitinib prostate cancer trial
        

Masitinib Prostate Cancer Trial Gains FDA and EMA Approval for Phase 3 Study

🚀 What’s the next big thing in prostate cancer treatment?

The recent FDA and EMA authorizations for the masitinib prostate cancer trial could revolutionize care for metastatic castrate-resistant prostate cancer (mCRPC). This groundbreaking study employs a biomarker-driven strategy to optimize treatment outcomes for patients like never before!

Dive into the full article to explore the implications of this targeted therapy and how it may change the future of precision medicine in oncology.

#SyenzaNews #Oncology #PrecisionMedicine #HealthTech

BEBT-908 DLBCL treatment
        

BEBT-908 DLBCL Treatment: A Milestone Approval for a First-in-Class Dual Inhibitor in China

🚀 Are we on the brink of a revolution in DLBCL treatment?

The recent conditional approval of **BEBT-908** by China’s National Medical Products Administration is not just a milestone for oncology, but potentially a game-changer for adults battling relapsed or refractory diffuse large B-cell lymphoma. With its dual-target mechanism, this first-in-class therapy offers promising efficacy and a well-thought-out access strategy that could reshape treatment standards.

Dive into the full article to discover how BEBT-908 is setting new benchmarks in both clinical outcomes and healthcare affordability.

#SyenzaNews #oncology #pharmaceuticals #MarketAccess

AI Cost Implications
    

AI Clinician in Pediatric ICU: A Review and HEOR Perspective

🤖 What could AI Clinician support mean for pediatric ICU care?

A new collaboration between Imperial College London and CHOC is developing an AI system to guide treatment decisions in PICUs. This article reviews the initiative and examines its broader health system implications—offering a Health Economics and Outcomes Research (HEOR) perspective on how AI may shape efficiency, equity, and value in critical care.

Read on to explore how clinical innovation intersects with healthcare economics.

#SyenzaNews #AIinHealthcare #HEOR #PediatricCare #HealthInnovation #PICU

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.